Pharmacometric approach to assist dosage regimen design in neonates undergoing therapeutic hypothermia.
Journal
Pediatric research
ISSN: 1530-0447
Titre abrégé: Pediatr Res
Pays: United States
ID NLM: 0100714
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
01
04
2021
accepted:
08
08
2021
revised:
09
07
2021
pubmed:
9
9
2021
medline:
30
8
2022
entrez:
8
9
2021
Statut:
ppublish
Résumé
Therapeutic hypothermia (TH) is the treatment of choice for neonates diagnosed with perinatal asphyxia (PA). Dosing recommendations of various therapeutic agents including antimicrobials were not specifically available for the neonates undergoing TH. A systematic search methodology was used to identify pharmacokinetic (PK) studies of antimicrobials during TH. Antimicrobials with multiple PK studies were identified to create a generalizable PK model. Pharmacometric simulations were performed using the PUMAS software platform to reproduce the results of published studies. A suitable model that could reproduce the results of all other published studies was identified. With the help of a generalizable model, an optimal dosage regimen was designed considering the important covariates of the identified model. With the systematic search, only gentamicin had multiple PK reports during TH. A generalizable model was identified and the model predictions could match the reported/observed concentrations of publications. Birth weight and serum creatinine were the significant covariates influencing the PK of gentamicin in neonates. A dosage nomogram was designed using pharmacometric simulations to maintain gentamicin concentrations below 10 μg/mL at peak and below 2 μg/mL at trough. A generalizable PK model for gentamicin during TH in neonates was identified. Using the model, a dosing nomogram for gentamicin was designed. Dosing guidelines for antimicrobials during TH in neonates is lacking. This is the first study to identify the generalizable model for gentamicin during TH in neonates. Nomogram, proposed in the study, will aid the clinicians to individualize gentamicin dosing regimen for neonates considering the birth weight and serum creatinine.
Sections du résumé
BACKGROUND
Therapeutic hypothermia (TH) is the treatment of choice for neonates diagnosed with perinatal asphyxia (PA). Dosing recommendations of various therapeutic agents including antimicrobials were not specifically available for the neonates undergoing TH.
METHODS
A systematic search methodology was used to identify pharmacokinetic (PK) studies of antimicrobials during TH. Antimicrobials with multiple PK studies were identified to create a generalizable PK model. Pharmacometric simulations were performed using the PUMAS software platform to reproduce the results of published studies. A suitable model that could reproduce the results of all other published studies was identified. With the help of a generalizable model, an optimal dosage regimen was designed considering the important covariates of the identified model.
RESULTS
With the systematic search, only gentamicin had multiple PK reports during TH. A generalizable model was identified and the model predictions could match the reported/observed concentrations of publications. Birth weight and serum creatinine were the significant covariates influencing the PK of gentamicin in neonates. A dosage nomogram was designed using pharmacometric simulations to maintain gentamicin concentrations below 10 μg/mL at peak and below 2 μg/mL at trough.
CONCLUSIONS
A generalizable PK model for gentamicin during TH in neonates was identified. Using the model, a dosing nomogram for gentamicin was designed.
IMPACT
Dosing guidelines for antimicrobials during TH in neonates is lacking. This is the first study to identify the generalizable model for gentamicin during TH in neonates. Nomogram, proposed in the study, will aid the clinicians to individualize gentamicin dosing regimen for neonates considering the birth weight and serum creatinine.
Identifiants
pubmed: 34493833
doi: 10.1038/s41390-021-01714-0
pii: 10.1038/s41390-021-01714-0
pmc: PMC9411058
doi:
Substances chimiques
Anti-Bacterial Agents
0
Gentamicins
0
Creatinine
AYI8EX34EU
Types de publication
Journal Article
Systematic Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
249-254Informations de copyright
© 2021. The Author(s).
Références
Fattuoni, C., Palmas, F., Noto, A., Fanos, V. & Barberini, L. Perinatal asphyxia: a review from a metabolomics perspective. Molecules 20, 7000–7016 (2015).
doi: 10.3390/molecules20047000
Ahearne, C. E., Boylan, G. B. & Murray, D. M. Short and long term prognosis in perinatal asphyxia: an update. World J. Clin. Pediatr. 5, 67–74 (2016).
doi: 10.5409/wjcp.v5.i1.67
Giannoni, E. et al. Neonatal Sepsis of early onset, and hospital-acquired and community-acquired late onset: a Prospective Population-Based Cohort Study. J. Pediatr. 201, 106–114 (2018).
doi: 10.1016/j.jpeds.2018.05.048
Chiang, M. C., Jong, Y. J. & Lin, C. H. Therapeutic hypothermia for neonates with hypoxic ischemic encephalopathy. Pediatr. Neonatol. 58, 475–483 (2017).
doi: 10.1016/j.pedneo.2016.11.001
Datta, V. Therapeutic hypothermia for birth asphyxia in neonates. Indian J. Pediatr. 84, 219–226 (2017).
doi: 10.1007/s12098-016-2266-0
Lemyre, B. & Chau, V. Hypothermia for newborns with hypoxic-ischemic encephalopathy. Paediatr. Child Health 23, 285–291 (2018).
doi: 10.1093/pch/pxy028
Silveira, R. C. & Procianoy, R. S. Hypothermia therapy for newborns with hypoxic ischemic encephalopathy. J. Pediatr. 91, S78–S83 (2015).
doi: 10.1016/j.jped.2015.07.004
Zanelli, S., Buck, M. & Fairchild, K. Physiologic and pharmacologic considerations for hypothermia therapy in neonates. J. Perinatol. 31, 377–386 (2011).
doi: 10.1038/jp.2010.146
Tanigasalam, V., Bhat, V., Adhisivam, B. & Sridhar, M. G. Does therapeutic hypothermia reduce acute kidney injury among term neonates with perinatal asphyxia?—a randomized controlled trial. J. Matern. Fetal Neonatal Med. 29, 2545–2548 (2016).
pubmed: 26456813
Solevag, A. L., Schmolzer, G. M. & Cheung, P. Y. Novel interventions to reduce oxidative-stress related brain injury in neonatal asphyxia. Free Radic. Biol. Med. 142, 113–122 (2019).
doi: 10.1016/j.freeradbiomed.2019.04.028
Sheiner, L. B. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab. Rev. 15, 153–171 (1984).
doi: 10.3109/03602538409015063
Bonate, P. L. Clinical trial simulation in drug development. Pharm. Res. 17, 252–256 (2000).
doi: 10.1023/A:1007548719885
Rackauckas, C. et al. Accelerated predictive healthcare analytics with pumas, a high performance pharmaceutical modeling and simulation platform. bioRxiv https://doi.org/10.1101/2020.11.28.402297 (2020).
Frymoyer, A., Meng, L., Bonifacio, S. L., Verotta, D. & Guglielmo, B. J. Gentamicin pharmacokinetics and dosing in neonates with hypoxic ischemic encephalopathy receiving hypothermia. Pharmacotherapy 33, 718–726 (2013).
doi: 10.1002/phar.1263
Coppini, R., Simons, S. H. P., Mugelli, A. & Allegaert, K. Clinical research in neonates and infants: challenges and perspectives. Pharm. Res. 108, 80–87 (2016).
doi: 10.1016/j.phrs.2016.04.025
Patel, P. et al. Dried blood spots and sparse sampling: a practical approach to estimating pharmacokinetic parameters of caffeine in preterm infants. Br. J. Clin. Pharmacol. 75, 805–813 (2013).
doi: 10.1111/j.1365-2125.2012.04392.x
Dahmane, E. et al. Clinical pharmacology-driven translational research to optimize bedside therapeutics of sotalol therapy. Clin. Transl. Sci. 12, 648–656 (2019).
doi: 10.1111/cts.12670
Liu, T., Ivaturi, V. & Gobburu, J. Integrated model to describe morphine pharmacokinetics in humans. J. Clin. Pharmacol. 59, 1070–1077 (2019).
doi: 10.1002/jcph.1400
Liu, T., Lewis, T., Gauda, E., Gobburu, J. & Ivaturi, V. Mechanistic population pharmacokinetics of morphine in neonates with abstinence syndrome after oral administration of diluted tincture of opium. J. Clin. Pharmacol. 56, 1009–1018 (2016).
doi: 10.1002/jcph.696
Bijleveld, Y. A. et al. Population pharmacokinetics of amoxicillin in term neonates undergoing moderate hypothermia. Clin. Pharm. Ther. 103, 458–467 (2018).
doi: 10.1002/cpt.748
Cies, J. J., Fugarolas, K. N., Moore, W. S., Mason, R. W. & Menkiti, O. R. Population pharmacokinetics and pharmacodynamic target attainment of ampicillin in neonates with hypoxemic-ischemic encephalopathy in the setting of controlled hypothermia. Pharmacotherapy 37, 456–463 (2017).
doi: 10.1002/phar.1916
Cristea, S. et al. Amikacin pharmacokinetics to optimize dosing in neonates with perinatal asphyxia treated with hypothermia. Antimicrob. Agents Chemother. 61, e01282–17 (2017).
doi: 10.1128/AAC.01282-17
Bijleveld, Y. A. et al. Altered gentamicin pharmacokinetics in term neonates undergoing controlled hypothermia. Br. J. Clin. Pharmacol. 81, 1067–1077 (2016).
doi: 10.1111/bcp.12883
Cies, J. J., Habib, T., Bains, V., Young, M. & Menkiti, O. R. Population pharmacokinetics of gentamicin in neonates with hypoxemic-ischemic encephalopathy receiving controlled hypothermia. Pharmacotherapy 38, 1120–1129 (2018).
doi: 10.1002/phar.2186
Frymoyer, A. et al. Every 36-h gentamicin dosing in neonates with hypoxic-ischemic encephalopathy receiving hypothermia. J. Perinatol. 33, 778–782 (2013).
doi: 10.1038/jp.2013.59
Liu, X., Borooah, M., Stone, J., Chakkarapani, E. & Thoresen, M. Serum gentamicin concentrations in encephalopathic infants are not affected by therapeutic hypothermia. Pediatrics 124, 310–315 (2009).
doi: 10.1542/peds.2008-2942
Mark, L. F., Solomon, A., Northington, F. J. & Lee, C. K. Gentamicin pharmacokinetics in neonates undergoing therapeutic hypothermia. Ther. Drug Monit. 35, 217–222 (2013).
doi: 10.1097/FTD.0b013e3182834335
Ting, J. Y., Kwan, E., McDougal, A. & Osiovich, H. Pharmacokinetics of gentamicin in newborns with moderate-to-severe hypoxic-ischemic encephalopathy undergoing therapeutic hypothermia. Indian J. Pediatr. 82, 119–125 (2015).
doi: 10.1007/s12098-014-1527-z
Choi, D. W., Park, J. H., Lee, S. Y. & An, S. H. Effect of hypothermia treatment on gentamicin pharmacokinetics in neonates with hypoxic-ischaemic encephalopathy: a systematic review and meta-analysis. J. Clin. Pharm. Ther. 43, 484–492 (2018).
doi: 10.1111/jcpt.12711
Alaro, D., Bashir, A., Musoke, R. & Wanaiana, L. Prevalence and outcomes of acute kidney injury in term neonates with perinatal asphyxia. Afr. Health Sci. 14, 682–688 (2014).
doi: 10.4314/ahs.v14i3.26
Nouri, S. et al. Acute renal failure in full term neonates with perinatal asphyxia. Prospective study of 87 cases. Arch. Pediatr. 15, 229–235 (2008).
doi: 10.1016/j.arcped.2008.01.011
Rhodin, M. M. et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr. Nephrol. 24, 67–76 (2009).
doi: 10.1007/s00467-008-0997-5
Gupta, C., Massaro, A. N. & Ray, P. E. A new approach to define acute kidney injury in term newborns with hypoxic ischemic encephalopathy. Pediatr. Nephrol. 31, 1167–1178 (2016).
doi: 10.1007/s00467-016-3317-5
De Cock, R. F. et al. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin. Pharmacokinet. 51, 105–117 (2012).
doi: 10.2165/11595640-000000000-00000
Topcu, H. O. et al. Birth weight for gestational age: a reference study in a tertiary referral hospital in the middle region of Turkey. J. Chin. Med. Assoc. 77, 578–582 (2014).
doi: 10.1016/j.jcma.2014.05.013
McWilliam, S. J., Antoine, D. J., Smyth, R. L. & Pirmohamed, M. Aminoglycoside-induced nephrotoxicity in children. Pediatr. Nephrol. 32, 2015–2025 (2017).
doi: 10.1007/s00467-016-3533-z
Siber, G. R., Echeverria, P., Smith, A. L., Paisley, J. W. & Smith, D. H. Pharmacokinetics of gentamicin in children and adults. J. Infect. Dis. 132, 637–651 (1975).
doi: 10.1093/infdis/132.6.637
Sampson, M. R. et al. Predictive performance of a gentamicin population pharmacokinetic model in neonates receiving full-body hypothermia. Ther. Drug Monit. 36, 584–589 (2014).
doi: 10.1097/FTD.0000000000000056